Navigation Links
Unigene Appoints David Moskowitz as Chief Financial Officer
Date:3/15/2012

uality, frequency and regulatory compliance of the firm's research product. During his tenure at Friedman Billings Ramsey & Co., Mr. Moskowitz played integral roles in strengthening the firm's equity research division, where he expanded the team from three to 12 analysts, and rebuilding its healthcare investment banking practice, growing the unit from zero to 12 employees within a year. 

Mr. Moskowitz holds an MBA in Finance/Pharmaceutical Industry Studies from Fairleigh Dickinson University and a BS in Pharmacy from Rutgers University. He currently holds Series 7, 24 (Principal), 63, 86, and 87 licenses and is a registered pharmacist.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, including statements relating to whether: Tarsa's efforts to seek FDA approval for OSTORA, including the possible timing of an NDA submission in the second half of 2012; Tarsa's use of the proceeds from its convertible promissory note and warrant financing; OSTORA's potential to become the first orally delivered peptide approved by the FDA; approval (if any) of OSTORA will further validate the Company's oral peptide drug
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Unigene to Present at IBCs 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference
2. Unigene Announces Key Appointments as Biotechnologies Strategic Business Unit Continues to Grow in 2012
3. Unigene Laboratories Granted US Patent for Peptide-Based Technology for Treatment of Obesity
4. Unigene Provides 2012 Business Outlook
5. Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9
6. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
7. Unigene Strengthens Board with the Appointment of Walgreens Executive, Thomas J. Sabatino, Jr.
8. Unigene Reports Third Quarter 2011 Financial Results
9. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
10. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
11. BioDrain Medical Inc. Appoints New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013  This year alone, The ... 300 research projects with one goal in mind: Discovering ... "Team In Training" (TNT), a flagship LLS fundraising campaign ... program, is marking its landmark 25 th anniversary. ... $875 million in research to discover and deliver breakthrough ...
(Date:6/19/2013)... YORK , June 19, 2013 ... brand new infographic summary of the results from ... a third of all respondents stated that CROs would be ... 50% of respondents will be running 6 or more clinical ... with the Clinical Trial Supply USA ...
(Date:6/18/2013)... YORK , June 18, 2013  Intercept Pharmaceuticals, ... biopharmaceutical company focused on the development and commercialization of ... today announced the pricing of an underwritten public offering ... public offering price of $33.01 per share.  In addition, ... purchase up to an additional 259,500 shares of common ...
Breaking Medicine Technology:Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... PLAINS, N.Y., AUG. 2 Two major studies,published today ... doctors,better identify pregnant women at risk for preterm delivery ... Foundation said today. In one large multi-center trial ... (most of whom had no prior history of preterm ...
... - Access to Large Population of Glioblastoma Patients Expected ... Phase ll Study of Promising New Approach -, ... PPHM ), a clinical stage biopharmaceutical,company developing targeted monoclonal ... infection, today announced that the first,patient has been administered ...
Cached Medicine Technology:Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 3Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 4
(Date:6/19/2013)... 2013) In early April, senior leaders from medical, ... Connecticut, to discuss one question: how can first responders ... , The preliminary results of this discussion are now ... The Hartford Consensus ," a concept paper published in ... of Trauma and Acute Care Surgery , official ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Effective Environmental Services ... of new websites. These online links are devoted to a ... Tank cleaner, Organic Odor Control Mold Magician and others. , ... fish and animals in the water as well as living ... sludge buildup that can accumulate at the bottom of a ...
(Date:6/19/2013)... Ky. (PRWEB) June 19, 2013 Dental ... during sedation because from minor to moderate sedation, a ... Oregon Board of Dentistry is the latest to update ... moderate and deep sedation in an effort to increase ... the Oregon Dental Practice Act goes into effect July ...
(Date:6/19/2013)... Brightree LLC , the leading provider of cloud-based ... care industry, has been ranked for the first time - ... (HCI 100) list. This prestigious list features the top ... revenue during the last fiscal year. Since 2005, Brightree’s revenue ... the company has built its organization to more than 500 ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 At a Travel ... positive changes and growth that has occurred over the last ... club. , Shuman said, "Travel Services has added vendors, lowered ... beyond belief. Membership is up, even in the tough ... the demands of members." , Having been in the Travel ...
Breaking Medicine News(10 mins):Health News:Hartford consensus aims to improve survival after mass shootings 2Health News:Effective Environmental Services Launch New Websites to Serve Customers 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2
... of the BBVA Foundation, Francisco Gonzlez, Jose Baselga, ... Center (MGHCC), and Andrs de Kelety, Managing Director ... in Barcelona, yesterday signed the agreement creating the ... the event was the Foundation,s Director, Mr. Rafael ...
... (HealthDay News) -- Women and younger men account for a ... are less likely than older men to receive preventive medications ... Researchers evaluated more than 3,000 heart attack patients treated at ... and found that 70.3 percent of them had not been ...
... study to investigate the tolerability of the breast cancer drug ... stop taking their prescribed therapy early because of problems with ... of the research paper, published today in the cancer journal ... 64 male breast cancer patients at their institution who had ...
... rely on recombinant, protein-based drugs must often endure ... intravenous therapy. Researchers at Children,s Hospital Boston demonstrate ... engineered cells, could secrete the drug on demand ... issue of the journal Blood , they ...
... By Randy Dotinga HealthDay Reporter , TUESDAY, ... whole-body vibration doesn,t appear to improve the bone health ... osteoporosis. The treatment -- which involves standing on a ... -- showed promise in animals. But researchers, who hoped those ...
... read will be one of the topics of a conference ... co-sponsored by the UC Davis Center for Mind and Brain, ... Visual Learning, and the departments of psychology and linguistics at ... to read, said David Corina, professor in the Department of ...
Cached Medicine News:Health News:Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance 2Health News:Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance 3Health News:Women, Younger Men Under-Treated Before Heart Attack: Study 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 3Health News:Engineered, drug-secreting blood vessels reverse anemia in mice 2Health News:Engineered, drug-secreting blood vessels reverse anemia in mice 3Health News:Whole-Body Vibration Doesn't Build Bone After All: Study 2Health News:Visual language, cognition and deaf education topics of summit 2
... Steerability - Use the Attain Prevail's ... catheters and guide wires, to obtain the ... Inject contrast media for improved visualization of ... needed with tip deflection. Telescoping - ...
Attain™ Left-heart Lead Options to Fit Your Patient's Anatomy. Navigate moderately to greatly angled veins with high tortuosity....
... Mosaic, the third generation tissue valve from ... tissue valve available. The Mosaic valve builds ... and is an excellent choice for patients ... with a tissue valve. For more than ...
... Mitral bioprosthesis is a portrait ... based on 25 years of ... makes it an excellent choice ... replacement--particularly elderly patients and those ...
Medicine Products: